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Abstract
Background: Selection bias occurs when recruiters selectively enrol patients into the trial based on what the next
treatment allocation is likely to be. This can occur even if appropriate allocation concealment is used if recruiters
can guess the next treatment assignment with some degree of accuracy. This typically occurs in unblinded trials
when restricted randomisation is implemented to force the number of patients in each arm or within each centre
to be the same. Several methods to reduce the risk of selection bias have been suggested; however, it is unclear
how often these techniques are used in practice.
Methods: We performed a review of published trials which were not blinded to assess whether they utilised
methods for reducing the risk of selection bias. We assessed the following techniques: (a) blinding of recruiters;
(b) use of simple randomisation; (c) avoidance of stratification by site when restricted randomisation is used; (d)
avoidance of permuted blocks if stratification by site is used; and (e) incorporation of prognostic covariates into
the randomisation procedure when restricted randomisation is used. We included parallel group, individually
randomised phase III trials published in four general medical journals (BMJ, Journal of the American Medical
Association, The Lancet, and New England Journal of Medicine) in 2010.
Results: We identified 152 eligible trials. Most trials (98 %) provided no information on whether recruiters were
blind to previous treatment allocations. Only 3 % of trials used simple randomisation; 63 % used some form of
restricted randomisation, and 35 % did not state the method of randomisation. Overall, 44 % of trials were
stratified by site of recruitment; 27 % were not, and 29 % did not report this information. Most trials that did
stratify by site of recruitment used permuted blocks (58 %), and only 15 % reported using random block sizes.
Many trials that used restricted randomisation also included prognostic covariates in the randomisation
procedure (56 %).
Conclusions: The risk of selection bias could not be ascertained for most trials due to poor reporting. Many trials
which did provide details on the randomisation procedure were at risk of selection bias due to a poorly chosen
randomisation methods. Techniques to reduce the risk of selection bias should be more widely implemented.
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Background
Well-conducted randomised controlled trials (RCTs) are
viewed as the ‘gold standard’ for comparing different in-
terventions, as they are not subject to the same con-
founding as non-randomised studies. Randomisation
(when performed correctly) guarantees that, on average,
treatment groups will be well-balanced for both known
and unknown factors, thus ensuring an unbiased esti-
mate of the treatment effect. However, this guarantee of
balance only occurs when randomisation is performed
correctly; that is, when the probability of a patient being
enrolled does not depend on the probability of them be-
ing assigned to a particular treatment group. Otherwise,
the trial will be at risk of selection bias.
Selection bias occurs when those in charge of the
recruitment or enrolment of patients (recruiters) select-
ively enrol patients into the trial based on what the next
treatment allocation is likely to be. For example, if a
recruiter believes the next allocation will be the inter-
vention, they may wait to enrol a very sick patient, as
they do not want to ‘waste’ an intervention allocation on
a relatively healthy patient who is less likely to need it.
This can lead to substantially biased estimates of treat-
ment effect and misleading conclusions [1–9]. Selection
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bias is primarily an issue in RCTs where patients are
enrolled sequentially (rather than all at once), and when
recruiters can decide whether or not to enrol each eligible
patient.
Selection bias depends on the ability of the recruiter
to guess with greater than 50 % probability what the
next treatment allocation will be. This could happen if,
for example, the recruiter had access to the randomisa-
tion list, and knew what treatment each patient would
be assigned to before enrolling them. For this reason,
allocation concealment has been recommended as an
essential tool for RCTs [7, 10, 11]. Allocation conceal-
ment is ‘a technique used to prevent selection bias by con-
cealing the allocation sequence from those assigning
participants to intervention groups, until the moment of
assignment’ (http://www.consort-statement.org/resources/
glossary).
However, even if appropriate allocation concealment is
used and recruiters do not have access to allocation list
before enrolling patients, they still may be able to guess
what the next allocation will be based on the method of
randomisation. This is primarily a concern in unblinded
trials, where investigators are aware of each patient’s
treatment assignment. However, this could also be an
issue in blinded trials where there is a risk of unblinding:
for example, because side effects may occur for patients
in one arm only. Brown et al. [12] found that 16 % of
the investigators they surveyed had admitted to keeping
track of the number of allocations to each treatment
group in an attempt to predict the next allocation. This
type of behaviour has led to the identification of a num-
ber of RCTs which may have been affected by selection
bias [13–15]. Because the possibility of selection bias is
rarely reported in trial publications, it is likely that the
overall problem is underreported. Selection bias can have
serious implications for patient healthcare; the distortion
of trial results could lead ineffective interventions appear-
ing helpful or harmful interventions appearing safe. The
purpose of this article is to highlight some simple methods
to prevent selection bias, and assess how often these
methods are being used in practice.
Methods
We begin by describing the problem of selection bias in
more detail, and then highlight some simple methods to
reduce the risk (summarised in Table 1). We assume
that the trial is open-label (unblinded), and that there is
adequate allocation concealment.
Selection bias
For trials that use adequate allocation concealment, se-
lection bias can still be a problem if recruiters can guess
the next allocation with greater than 50 % probability.
This can occur when restricted randomisation is used.
Restricted randomisation involves forcing the treatment
groups to be similar in some way: for example, by re-
quiring that a similar number of patients are assigned to
each treatment group. The most common methods of
restricted randomisation are permuted blocks and mini-
misation (described below) [16].
Restricted randomisation can increase the risk of se-
lection bias as follows; consider a trial in which patients
are randomised using permuted blocks of size 4. This
design forces the number of patients in each treatment
group to be equal at the end of each block. This means
that the imbalance between groups can never be more
than two patients. When the imbalance between groups
is 1, the recruiter will be able to correctly guess the next
allocation with 83 % probability; when the imbalance is
2, this probability increases to 100 %.
Table 1 Methods to reduce the risk of selection bias in non-double-blind clinical trials*
Techniques Rationale Effect on risk of selection bias
Use blinded recruiters If recruiters are blind to previous trial allocations, they will be unable to
predict the next allocation
Risk of selection bias will be
eliminated provided the blinding is
maintained
Use simple (unrestricted)
randomisation
Recruiters cannot guess the next allocation with any degree of
accuracy
Risk of selection bias will be
eliminated
If restricted randomisation is used, do
not stratify by site of recruitment
The probability of the allocation will depend on previous allocations at
other sites, which recruiters are unlikely to have access to, making an
accurate guess more difficult
Risk of selection bias will be
reduced, but not necessarily
eliminated
When randomisation is stratified by
site, avoid permuted blocks
Permuted blocks stratified by site will maximise the probability of
correctly guessing the next allocation. Using alternative randomisation
methods will reduce the probability of correctly guessing the next
allocation
Risk of selection bias will be
reduced, but not necessarily
eliminated
When restricted randomisation is
used, stratify by prognostic covariates
as well
There is typically less variation in prognoses for patients with the same
covariate pattern, making it more difficult for investigators to identify
patients with a specific prognosis to enrol into the trial when their
preferred treatment is more likely
Risk of selection bias will be
reduced, but not necessarily
eliminated
*This table assumes that allocation concealment has been appropriately implemented
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Methods to reduce the risk of selection bias
Simple randomisation
Simple randomisation (sometimes also referred to as
‘complete’ or ‘unrestricted’ randomisation) is both the
simplest and most effective method to prevent selection
bias. Simple randomisation works by assigning each pa-
tient to one of the treatment groups with a certain
probability (usually 50 %); this probability is the same
for every patient, regardless of previous allocations. For
example, consider a trial where 15 of the first 20 pa-
tients were assigned to the intervention, and only 5 to
the control; when the 21st patient presented for ran-
domisation, they would still have an equal chance of
being assigned to either treatment group, regardless of
the imbalance in numbers. Because the probability is al-
ways the same, recruiters will not be able to guess with
any accuracy which treatment the patient will be assigned
to (as they would essentially be trying to guess the results
of a coin-flip); therefore, selection bias cannot occur in
this scenario.
In practice, simple randomisation is infrequently used
[16, 17], possibly because investigators prefer random-
isation methods which provide balance in the number
of patients assigned to each treatment group. However,
provided the overall sample size is not too small, this
lack of balance has only a very small impact on power,
and should not be used as a reason to avoid simple ran-
domisation [6]. Therefore, we agree with others that
simple randomisation should be used more frequently
in practice [8, 17, 18].
Do not stratify by site of recruitment if restricted
randomisation is used
Despite the appeal of simple randomisation, some form
of restricted randomisation is usually employed in prac-
tice. In trials with multiple sites of recruitment, the
number of patients allocated to each arm can be forced
to be similar in two different ways; either by forcing the
number within each site to be the same (stratified by
site), or by forcing the overall numbers to be the same,
regardless of the numbers within each site (not strati-
fied by site).
The risk of selection bias is most pronounced when
randomisation is stratified by site of recruitment; that
is, when the randomisation procedure is restricted to
ensure an equal number of patients are allocated to
each treatment group within each site. In this case, the
probability of the next allocation depends solely on the
previous allocations at that site, which the recruiters
may have access to. However, if randomisation is not
stratified by site, then the probability of the next alloca-
tion will also depend on the previous allocations at all
the other sites, which the recruiter is unlikely to have
access to.
Therefore, even if restricted randomisation is used, the
risk of selection bias can be reduced by not stratifying
by site of recruitment. Investigators often stratify by site
of recruitment as they are concerned that if between-
centre differences are large, a chance imbalance in the
number of patients allocated to each treatment within a
site could affect results. However, chance imbalances
within sites can be accounted for during the analysis by
adjusting for site-effects [19–22], and so stratification by
site during randomisation is generally not necessary.
If randomisation is stratified by site, avoid permuted blocks
Despite the increased risk of selection bias that accom-
panies stratification by site, it is still commonly used. In
some cases, this may be due to administrative or prac-
tical reasons: for example when separate randomisation
lists must be kept at each site, or when there is only one
site and so any restriction on the number of patients
assigned to each treatment group is equivalent to strati-
fying by site. However, it should be noted that in both of
these cases, unrestricted randomisation could still be
used (e.g. by generating the randomisation list for each
site using simple randomisation).
If randomisation is stratified by site, the best method
for reducing the risk of selection bias is to avoid the use
of permuted blocks, as this has been shown to substan-
tially increase the probability of correctly guessing the
next allocation compared to other methods. Common
suggestions for improving the performance of permuted
blocks are to randomly vary the block size, and to use
large block sizes. Although both approaches will help,
neither will reduce the risk to an acceptable level [4, 23].
Therefore, permuted blocks stratified by site of recruit-
ment should be avoided.
A preferable alternative is minimisation, which in-
volves allocating the patient to whichever treatment
arm minimises the imbalance in a set of baseline covar-
iates. Minimisation can maintain some balance within
centres, while also reducing the probability of correctly
guessing the next allocation [12]. This is partly because
the next allocation at each centre will depend on covar-
iate information for patients from other centres, which
recruiters are unlikely to know. Minimisation should
only be used with a random element (that is, by assign-
ing patients to the treatment group which minimises
the imbalance with a degree of probability, rather than
in a deterministic way) [24]. Additionally, centre should
be included as a minimisation factor like any other
covariate (as opposed to using a stratified approach,
where the minimisation procedure is performed separ-
ately within each site). Other alternatives to reduce the
risk of selection bias when stratifying by site are also
available, such as a stratified urn design [25]. However,
although these techniques will reduce selection bias
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compared to permuted blocks, it is still preferable to
avoid stratifying by site altogether.
If restricted randomisation is used, balance on prognostic
covariates as well
When restricted randomisation is used, balancing or
stratifying on prognostic factors could help to combat
selection bias. This works as follows: consider a trial
using permuted blocks. If the recruiter knows that
more patients have been allocated to the control, they
can guess that the next allocation is likely to be to the
intervention. Depending on their beliefs (conscious or
subconscious), they may wish to enrol a relatively sick
or relatively healthy patient for this allocation. The re-
cruiter therefore needs to be able to find a patient who
is relatively sick or healthy, compared to those who
have been previously enrolled.
Imagine if the patient’s age and their disease stage have
been included as stratification factors during randomisa-
tion. Even if the recruiter can guess the next allocation,
they still need to be able to find a patient to enrol who
is much sicker or healthier than other patients of the
same age and disease stage. This is clearly a much more
difficult task, as there will typically be less variation in
prognosis for patients with the same covariate patterns,
making it more difficult to identify patients with specific
prognoses. This becomes increasingly more difficult the
more prognostic covariates that are added to the ran-
domisation procedure (although it should be noted that
increasing the number of stratification factors has impli-
cations for the analysis as well [16, 26, 27]).
Therefore, when restricted randomisation is used, we
would recommend also including prognostic covariates
in the randomisation process. However, we caution that
this is approach is not a valid reason to use a randomisa-
tion method that increases the risk of selection bias,
such as stratification by site of recruitment; it is still
preferable to use a method of randomisation that com-
pletely eliminates the risk of selection bias, such as simple
randomisation.
Ensure that those enrolling patients are blinded to previous
treatment allocations
Even if a trial is unblinded, it may still be possible to
blind recruiters (the people who recruit and enrol pa-
tients into the trial) [28]. This could be done by using
personnel who are not otherwise involved in patient
care as recruiters. If they are blinded, they will not be
aware of the previous trial allocations and, therefore,
will not be able to predict the next allocation.
Review of published trials
We performed a review of published trials to investi-
gate whether investigators are taking adequate steps to
reduce the risk of selection bias. We included parallel
group, individually randomized, controlled trials which
were not fully blinded. We defined a trial to be not fully
blind when at least some trial personnel were not blinded
to treatment allocation. This included (but was not limited
to) participants, those administering the intervention,
those providing medical care apart from the intervention,
and those assessing outcomes. We excluded trials which
were described as double-blind, stated that everyone in-
volved in the study was blinded, or which used a placebo
or sham treatment that was described as being identical to
the intervention in terms of appearance. We also excluded
pilot and phase I or II trials, as well as articles that re-
ported only secondary analyses.
We included trials that were published in one of four
major medical journals in 2010 (BMJ, Journal of the
American Medical Association, The Lancet, and New
England Journal of Medicine). Trials were identified
from the electronic table of contents for each journal.
One reviewer determined whether trials met the eligi-
bility criteria for all trials identified; a second reviewer
assessed this for a subset of trials, and agreement was
found to be 100 %.
We extracted data onto a pre-piloted, standardised
form. This included information on the blinding status
of the trial, whether the randomisation procedure was
stratified by site of recruitment (i.e. whether it would
be possible for recruiters to keep track of each previous
allocation at their site), whether the recruiters were
blinded to previous allocations, and details on the ran-
domisation method used. All trials were extracted by
two independent reviewers, and disagreements were re-
solved by discussion.
Results
We identified 152 eligible trials. General trial characteris-
tics are shown in Table 2. Only 3 (2 %) stated whether
those enrolling or recruiting patients were aware of previ-
ous allocations (2 were blinded, 1 was unblinded); 149
(98 %) gave no information on whether recruiters were
blinded to previous treatment allocations. In most cases,
the trial report did not state who was involved in recruit-
ing patients, and whether this person had any other role
in the trial, such as delivering the intervention, providing
other aspects of patient care, or assessing outcomes.
Only 4 trials (3 %) used simple randomisation; the rest
used either restricted randomisation (n = 95, 63 %), or did
not state the method of randomisation (n = 53, 35 %). Of
the trials using some form of restricted randomisation,
most used permuted blocks (n = 72, 76 %) or minimisa-
tion (n = 21, 22 %). Overall, 67 (44 %) of trials stratified
randomisation by site of recruitment; 41 (27 %) did not,
and 44 (29 %) did not provide this information.
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Results for trials which stratified by site of recruitment
Amongst the 67 trials which stratified by site of recruit-
ment, 65 (97 %) did not provide information on whether
recruiters were blinded (Table 3). Most trials (n = 39,
58 %) used stratified permuted blocks; 13 (19 %) used
minimisation, 3 (4 %) used another method of random-
isation, and 12 (18 %) did not state which method they
used.
Only 23 of the 39 trials (59 %) which used permuted
blocks stated the block size(s), and only 6/39 (15 %) re-
ported using random block sizes. Seventeen out of
thirty-nine 17/39 (44 %) did not state whether block
sizes were random or not. Most trials used small block
sizes (median 8, interquartile range (IQR) 4 to 11). Of
the 13 trials using minimisation, 12 (92 %) did not state
whether it was deterministic or not.
Discussion
Selection bias can subvert the randomisation process in
RCTs, leading to biased estimates of treatment effect
and misleading conclusions. For this reason, allocation
concealment is regarded as an essential component of
RCTs. However, selection bias can still occur even with
adequate allocation concealment if the method of ran-
domisation is poorly chosen.
Our review found that very few trials used techniques
that would eliminate the risk of selection bias, such as
simple randomisation (3 %) or blinding of recruiters (1 %).
Most trials used some form of restricted randomisation
(63 %), and many trials were stratified by site of recruit-
ment (44 %). Furthermore, a substantial proportion of
trials did not provide adequate information on whether
randomisation was restricted (35 %) or whether it was
stratified by site (29 %), effectively preventing readers from
assessing the risk of selection bias. A comparison to
Hewitt and Torgerson’s review of trials published in 2002
[17] indicates that reporting on the method of randomisa-
tion has not improved in the 8 years between reviews
(method of randomisation unclear 34 % in 2002 versus
35 % in 2010), while the use of simple randomisation may
have decreased (9 % in 2002 versus 3 % in 2010).
These findings indicate that a substantial proportion of
unblinded trials are at risk of selection bias. This is sur-
prising, given the relative simplicity with which methods
to reduce this risk can be implemented. For example,
simple randomisation is by far the easiest method of
randomisation to implement, and has little effect on trial
Table 2 The use of methods to reduce the risk of selection bias
Trials (n = 152)
Recruiters blinded? – number (%)
No 1 (1)
Yes 2 (1)
Not stated 149 (98)
Used simple or restricted randomisation? – number (%)
Simple randomisation 4 (3)
Restricted randomisation 95 (63)
Not stated 53 (35)
Type of restricted randomisation used – number (%)
Permuted block 72/95 (76)
Minimisation 21/95 (22)
Other 2/95 (2)
Balanced for prognostic factors after restricted
randomisation? – number (%)
No 42/95 (44)
Yes 53/95 (56)
Randomisation stratified by site of recruitment? –
number (%)
No 41 (27)
Yes 67 (44)
Not stated 44 (29)
Table 3 The use of methods to reduce the risk of selection bias
in trials that stratified by site of recruitment
Trials (n = 67)
Recruiters blinded? – number (%)
No 1 (1)
Yes 1 (1)
Not stated 65 (97)
Randomisation method – number (%)
Stratified permuted block 39 (58)
Minimisation 13 (19)
Other 3 (4)
Not stated 12 (18)
Block sizes stated? – number (%)
No 16/39 (41)
Yes 23/39 (59)
Were block sizes random? - number (%)
No 16/39 (41)
Yes 6/39 (15)
Not stated 17/39 (44)
Largest block size used – median (IQR) 8 (4 to 11)
Was minimisation deterministic? – number (%)
No 1/13 (8)
Yes 0/13 (0)
Not stated 12/13 (92)
Balanced for prognostic factors? – number (%)
No 27 (40)
Yes 40 (60)
Number of prognostic factors balanced – median (IQR) 2 (1 to 3)
IQR, interquartile range
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organisation or the statistical analysis. Likewise, adjusting
for site of recruitment in the analysis rather than stratify-
ing on it during randomisation is also relatively straight-
forward, and typically has no adverse impact on results.
Similarly, permuted blocks can often be replaced by
allocation methods which do not substantially increase
the probability of correctly guessing future allocations,
such as minimisation with a random element or urn
randomisation.
We therefore suggest that investigators conducting
unblinded trials (or double-blinded trials where the
blinding may not be entirely effective) should choose
randomisation methods that reduce the risk of selection
bias. This primarily involves simple randomisation, or
avoiding the use of stratification by site of recruitment
if restricted randomisation is employed. As discussed in
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines, details of re-
stricted randomisation schemes should not be shared
with trial investigators, as this information could make
it easier to correctly guess the next treatment allocation
[29]. However, it is important that the details of the
randomisation procedure is fully reported in the trial
publication, as this will enable readers to judge the risk of
bias. This description should include whether stratification
was employed, which stratification factors were used, the
block sizes (and whether they were random) for permuted
blocks, and whether a random component was used (and
its size) for minimisation. It would also be helpful for
investigators to report on who was involved in recruiting
and enrolling patients into the trial, whether they were
blinded to treatment allocation, and whether they had any
other role in the trial, such as delivering the intervention,
providing other aspects of medical care, or assessing
outcomes.
Conclusion
The risk of selection bias could not be ascertained for
most trials due to poor reporting. Many trials which
did provide details on the randomisation procedure
were at risk of selection bias due to a poorly chosen
randomisation methods. Investigators should choose
randomisation methods which eliminate or reduce the
risk of selection bias.
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